

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/029055 A1(51) International Patent Classification⁷: C07D 487/04,
487/06, 519/00, A61P 29/00BACON, Kevin [GB/JP]; 5-15-912, Koyo-cho Naka,
Higashinada-ku, Kobe-shi, Hyogo 658-0032 (JP).(21) International Application Number:
PCT/EP2003/010377(74) Common Representative: BAYER HEALTHCARE
AG; Law and Patents, Patents and Licensing, 51368
Leverkusen (DE).(22) International Filing Date:
18 September 2003 (18.09.2003)(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02021861.6 30 September 2002 (30.09.2002) EP(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).(71) Applicant (*for all designated States except US*): BAYER
HEALTHCARE AG [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SHIMADA, Mit-
suyuki [JP/JP]; 4-7-905, Kyobatejikatahigashigawa-cho,
Nara-shi, Nara 630-8323 (JP). MURATA, Toshiki [JP/JP];
1-3-501, Nakano-cho, Ikoma-shi, Nara 630-0267 (JP).
FUCHIKAMI, Kinji [JP/JP]; 7-1-8-A 103, Umemidai,
Kizu-cho, Soraku-gun, Kyoto 619-0215 (JP). TSU-
JISHITA, Hideki [JP/JP]; 1-37-2-522, Seikadai,
Seika-cho, Soraku-gun, Kyoto 619-0238 (JP). OMORI,
Naoki [JP/JP]; 1-4-8-A 102, Umemidai, Kizu-cho, So-
raku-gun, Kyoto 619-0213 (JP). KATO, Issei [JP/JP];
17-2-202, Surugamachi, Nara-shi, Nara 630-8357 (JP).
MIURA, Mami [JP/JP]; 1-1365-3-202, Daiwa-cho,
Gakuen, Nara 631-0041 (JP). URBAHNS, Klaus [DE/JP];
6-3-1-301, Kusugaoka-cho, Nada-ku, Kobe-shi, Hyogo
657-0024 (JP). GANTNER, Florian [AT/JP]; 1-5-40-302,
Dogashiba, Tennoji-ku, Osaka-shi, Osaka 540-0033 (JP).

Declaration under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii)) for all designations*

Published:

— *with international search report*
— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments**For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: FUSED AZOLE-PYRIMIDINE DERIVATIVES

(57) **Abstract:** The present invention relates to novel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphatidylinositol-3-kinase (PI3K) inhibition, especially for PI3K- γ inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K- γ activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoimmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis. The compounds of the present invention are also useful for pulmonary hypertension, renal failure, cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, diabetes and focal ischemia, since the diseases also relate to PI3K activity in a human or animal subject.

WO 2004/029055 A1